This is administered subcutaneously (under the skin) two to three times per week, and sometimes up to five days per week, for a course of about eight weeks 1 2
Caution should be exercised in patients with a history of gastrointestinal disease, as Wegovy may cause adverse effects in this system
Pestic Biochem Physiol 104:5864
Regulatory Status As of January 2026, a 7.2 mg once-weekly dose of Wegovy is approved for use in the UK for the treatment of obesity
This includes highly refined grains like white bread, white rice, and sugary cereals, as well as foods rich in added sugars such as soda, fruit juices without fiber, candy, and sweetened desserts